CoRegen
CoRegen, Inc.
CoRegen, Inc. is a pioneering biopharmaceutical company dedicated to the development of innovative treatments aimed at aggressive cancers and chronic diseases. Utilizing its proprietary master gene regulator platform, CoRegen works on harnessing the body’s immune system to combat cancer effectively.
Products & Team
Novel Cancer Therapy
CoRegen's main product is a cutting-edge cancer therapy designed to modify regulatory T cells (Tregs) with the aim of eliminating tumors and preventing their recurrence. The therapy focuses on effectively enhancing the immune response against cancer cells.
This innovative therapy addresses the significant issue of cancer's ability to evade the immune system, offering patients new hope particularly those who have limited options due to difficult-to-treat cancers.
Customers face major challenges such as the ineffectiveness of current treatments, severe side effects associated with traditional therapies, and the urgent need for effective solutions against aggressive forms of cancer.